Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.
Tag Archive for: KRAS
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.